These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Khouri IF Hematology Am Soc Hematol Educ Program; 2006; ():390-7. PubMed ID: 17124088 [TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271 [TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. Shimoni A; Giralt S; Khouri I; Champlin R Curr Oncol Rep; 2000 Mar; 2(2):132-9. PubMed ID: 11122834 [TBL] [Abstract][Full Text] [Related]
15. The choice of allogeneic or autologous hematopoietic transplantation for NHL. Hosing C; Champlin RE Cytotherapy; 2002; 4(3):259-69. PubMed ID: 12194722 [TBL] [Abstract][Full Text] [Related]
16. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies]. Michallet M; Dhedin N; Michallet AS Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365 [TBL] [Abstract][Full Text] [Related]
17. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Sorror ML; Storer BE; Maloney DG; Sandmaier BM; Martin PJ; Storb R Blood; 2008 Jan; 111(1):446-52. PubMed ID: 17916744 [TBL] [Abstract][Full Text] [Related]
18. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280 [TBL] [Abstract][Full Text] [Related]
19. Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective. Dreger P; Michallet M; Schmitz N Ann Oncol; 2000; 11 Suppl 1():49-53. PubMed ID: 10707779 [TBL] [Abstract][Full Text] [Related]
20. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D; Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]